Beyond Detection: Using ctDNA to Stratify Patients & Guide Personalized Cancer Vaccine Development in MRD

• Exploring how ctDNA positive versus negative status is being used to stratify patients in personalized cancer vaccine trials after surgery, and what a positive result does and does not tell us about clinical outcome
• Examining the open questions that sensitivity alone cannot answer, including how ctDNA relates to circulating tumor cells, how to interpret ctDNA shifts when immunotherapy destroys tumor, and the ethical implications of incidental findings from large panels in single-indication trials
• Sharing exploratory data and a trial designer’s perspective on what evidence is needed to link ctDNA to disease-free survival, and what that means for MRD as a regulatory endpoint

Speakers:

Fernando Kreutz

ceo

Cellvax